Treatment of an Early Kaposi’s Sarcoma Case Post Kidney Transplantation by Sirolimus: A Case Report
Najafi، Farzaneh نويسنده , , Kafaie، Parichehr نويسنده Dermatologist, Assistant Professor, Yazd Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. , , Neamatzadeh، Hossein نويسنده Department of Medical Genetics, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran. Neamatzadeh, Hossein
Kaposi᾽s sarcoma (KS) can develop in 0.06% to 4.1% of kidney transplant recipients. Here we describe a case of 50-year-old man who developed KS a few months after kidney transplantation. After transplantation, he had delayed graft function and was managed by anti-thymocyte globulin (ATG) for five days. At the discharge, his immunosuppressive therapy was prednisolone 20 mg/day, tTacrolimus (Pprograf®) 4 mg/day, and mycophenolate mofetil (MMF) 2 gr/day, while he also took Vvalcyte and diltiazem. Once diagnosed with KS, the Prograf® (tacrolimus) was replaced by prednisolone (5 mg/day) and sirolimus (2 mg/day). Gradually the skin nodule on the patient arm disappeared, and the others nodule on the right his leg was decreased. It seems that the examination of skin should be a part of regular follow-up and dermatologist examination is recommended every 6 months.